144657-66-9

Usage

Uses

Used in Pharmaceutical Industry:
1-(tert-Butoxycarbonyl)-3-formyl-7-azaindole, 3-Formyl-pyrrolo[2,3-b]pyridine-1-carboxylic acid tert-butyl ester is used as a reagent in the study of electrophilic fragment-based design of reversible covalent kinase inhibitors. Its unique chemical structure allows it to be a valuable tool in the development of new drugs targeting specific kinases, which are important proteins involved in various cellular processes and are often dysregulated in diseases such as cancer.
Used in Chemical Research:
In addition to its pharmaceutical applications, 1-(tert-Butoxycarbonyl)-3-formyl-7-azaindole, 3-Formyl-pyrrolo[2,3-b]pyridine-1-carboxylic acid tert-butyl ester can also be utilized in chemical research for the synthesis of various complex organic molecules. Its versatile structure and reactivity make it a promising candidate for the development of new chemical entities with potential applications in various fields, including materials science, agrochemistry, and environmental chemistry.

Upstream product

• 4649-09-6 1H-pyrrolo[2,3-b]pyridin-3-carbaldehyde 
• 24424-99-5 di-tert-butyl dicarbonate 
• 271-63-6 7-Azaindole 
• 5654-92-2 7-azagramine 

Downstream Products

• 1443528-04-8 C₃₅H₃₃N₃O₅S 
• 1443528-03-7 C₃₀H₃₁N₃O₄S 
• 1443528-02-6 C₃₄H₃₁N₃O₄S 
• 1443527-77-2 C₂₇H₂₅N₃O₂ 
• 1443527-92-1 C₂₃H₁₈N₄O₂ 
• 1443527-80-7 C₂₂H₁₇N₃ 
• 157561-90-5 2-cyano-3-(1H-pyrrolo[2,3-b]pyridin-3-yl)acrylamide 
• 1428969-54-3 2-((3-methoxyphenyl)amino)-2-phenyl-1-(1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone 
• 134235-82-8 (-)-(R)-7-azatryptophan 
• 144657-68-1 tert-butyl 3-(chloromethyl)-1H-pyrrolo[2,3-b]pyridine-1-carboxylate 
• 1268390-81-3 1-(2-methoxyl-5-chlorophenyl)-3-{1-[1-(t-butyloxycarbonyl)-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl]-1H-indol-4-yl}urea 
• 144657-67-0 tert-butyl 3-(hydroxymethyl)-1 H-pyrrolo[2,3-b]pyridine-1-carboxylate 

Relevant academic research and scientific papers

Asymmetric Synthesis of N-Fmoc-(S)-7-aza-tryptophan via Alkylation of Chiral Nucleophilic Glycine Equivalent

Ni(II)-complexes, derived from glycine Schiff bases with chiral tridentate ligands, have been used as powerful tools for the synthesis of structurally diverse tailor-made amino acids. In this manuscript, asymmetric alkylation reaction between chiral nucleophilic glycine derived Ni-complex and 3-(chloromethyl)-1H-pyrrolo[2,3-b]pyridine has been developed under convenient conditions, which affords the corresponding alkylated Ni-complex in 74 % yield and excellent diastereoselectivity (only one isomer). This reaction features convenient conditions and completely controlled diastereoselectivity, which provides a highly valuable approach for asymmetric synthesis of 7-aza-tryptophan.

PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS

The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.

VIRAL REPLICATION INHIBITORS

The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.

5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS

The present invention provides 5,6-bicyclic heteroaryl-containing urea compounds of Formula I or II and use of the same for treating conditions mediated by protein kinase such as VEGFR2, c-Met, PDGFRβ c-Kit, CSFlR, or EphA2.

RENIN INHIBITORS

Renin inhibitors, which are spirocyclic piperidine amides, of structural formula (I) and pharmaceutical compositions thereof useful in the treatment of cardiovascular diseases and renal insufficiency, wherein n, for each instance in which it occurs, is independently 0, 1, or 2; R1 is hydrogen, C1-6 -alkyl or C3-6 -cycloalkyl, wherein said C1-6 -alkyl or C3-6 -cycloalkyl group can be independently substituted with 1-3 halogens; A is (i) a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic monocyclic ring or (ii) a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring which is fused to another five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring, V is a bond or -(C=O)-, -CH(OH)-, -CH2- or =CH-; U is a bond or -CH2-, or for the case when V is =CH-, U is -CH=; X is =CH-, =CF-, =C(OR3)-, or -C=O-; and Y is =CH-, =CF-, =N-, or for the case when X is -C=O-, Y is -N(R3)-.

Syntheses of a potential fluorescence probe, (-)-(R)-7-azatryptophan, via alkylation of the (1R,4R)-camphor imine of tert-butylglycinate

The synthesis of (-)-(R)-7-azatryptophan (2) from commercially available 7-azaindole (4) is described.The key step involved the diastereoselective alkylation of tert-butyl acetate (3) with 1-(tert-butyloxycarbonyl-3-(iodomethyl)-7-azaindole (14).The alkylation, conducted at -100 deg C in a THF/HMPA solvent using potassium hexamethyldisilazide as the base, afforded 7 in a greater than 98 percent diastereomeric excess.Hydrolysis and deprotecting gave (-)-(R)-7-azatryptophan.